Moody Lynn & Lieberson, LLC Neurocrine Biosciences Inc Transaction History

Moody Lynn & Lieberson, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 23, 2024	BUY	$130.4 - $143.74 $2.92 Million - $3.22 Million	22,428 New	22,428 $3.09 Million
Q4 2022 Feb 01, 2023	SELL	$106.72 - $127.06 $3,735 - $4,447	-35 Reduced 0.1%	34,645 $4.14 Million
Q3 2022 Oct 26, 2022	SELL	$92.03 - $107.81 $460 - $539	-5 Reduced 0.01%	34,680 $3.68 Million
Q2 2022 Jul 28, 2022	BUY	$75.79 - $100.07 $2.63 Million - $3.47 Million	34,685 New	34,685 $3.38 Million
Q4 2020 Jan 26, 2021	SELL	$86.91 - $108.33 $899,605 - $1.12 Million	-10,351 Closed	0 $0
Q3 2020 Oct 28, 2020	BUY	$96.16 - $135.15 $995,352 - $1.4 Million	10,351 New	10,351 $995,000
Q4 2018 Jan 29, 2019	SELL	$68.32 - $124.36 $289,881 - $527,659	-4,243 Closed	0 $0
Q3 2018 Oct 29, 2018	BUY	$98.88 - $125.85 $419,547 - $533,981	4,243 New	4,243 $522,000

625

94.2M

632K

621K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $12B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Moody Lynn & Lieberson, LLC, based on Form 13F filings with the SEC.

Stay updated on Moody Lynn & Lieberson, LLC with notifications on news.